Boehringer Ingelheim collaborates with CDR-Life to develop antibody fragment-based therapeutics for geographic atrophy
GA is a progressive, irreversible retinal disease that occurs in patients with age-related macular degeneration (AMD) for which there is no current treatment. Together, with Boehringer Ingelheim’s expertise